Jefferies Reiterates Buy on Vertex Pharma (VRTX) Following Investor Event

October 28, 2016 7:54 AM EDT
Get Alerts VRTX Hot Sheet
Price: $81.26 +0.43%

Rating Summary:
    24 Buy, 17 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 29 | Down: 29 | New: 23
Trade VRTX Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Jefferies reiterated a Buy rating and $102.00 price target on Vertex Pharma (NASDAQ: VRTX) following an investor event. Jefferies thought VRTX made a good argument for the viability of their next-gen correctors despite some questions raised about their safety profiles. They pointed out that while the teratogenicity with '440 is not ideal, they are already seeing high interest among KOLs in testing the agent given its disease-modifying promise in CF. VRTX also clarified that the use of a 2-week dosing period for the '152 ph.II study does not relate to any tox concerns that would prevent them from dosing longer, and instead is because a shorter study will enable them to more quickly optimize the dose.

Analyst Brian Abrahams commented, "At their investor event at NACF this evening, which we attended, we believe VRTX made a strong case for the viability and promise of their next-gen correctors '440 and '152-- we believe helping reduce outstanding concerns about their profiles coming out of the earnings call earlier this week. We expect the stock to rebound somewhat and with our view shares approaching levels that bake in virtually no value for a 3x combo, we see compelling upside/ downside."

For an analyst ratings summary and ratings history on Vertex click here. For more ratings news on Vertex click here.

Shares of Vertex closed at $75.84 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Jefferies & Co, Earnings

Add Your Comment